Advertisement

Advertisement
Richard I. Fisher, MD, on Follicular Lymphoma: Optimizing First-Line Therapy

Richard I. Fisher, MD, on Follicular Lymphoma: Optimizing First-Line Therapy

Role of Radiotherapy for Patients With Refractory Lymphoma Receiving CAR T-Cell Therapy

Role of Radiotherapy for Patients With Refractory Lymphoma Receiving CAR T-Cell Therapy

Although the role of radiotherapy in chimeric antigen receptor (CAR) T-cell therapy for lymphoma is still evolving, radiotherapy “would be an ideal bridging therapy” for patients with chemorefractory diffuse large B-cell lymphoma, stated George Mikhaeel, MD, Professor of Radiation Oncology and Consultant Clinical Oncologist at Guy’s Cancer Centre, London, at the 2019 American Society for Radiation Oncology (ASTRO) Annual Meeting in Chicago. 

 

Pretreatment Vitamin D Deficiency and Outcomes in Hodgkin Lymphoma

In a study reported in the Journal of Clinical Oncology, Borchmann et al found that pretreatment vitamin D deficiency was associated with poorer progression-free and overall survival rates in patients receiving first-line treatment for Hodgkin lymphoma.

Immunotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Immunotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

Findings from the phase Ib KEYNOTE-013 and phase II KEYNOTE-170 trials reported in the Journal of Clinical Oncology by Armand et al indicated that pembrolizumab is highly active in relapsed or refractory primary mediastinal large B-cell lymphoma.

Long-Term Follow-up of Patients With Nodular Lymphocyte–Predominant Hodgkin Lymphoma Treated in GHSG Trials

In an analysis reported in the Journal of Clinical Oncology, Eichenauer et al found that patients with newly diagnosed nodular lymphocyte–predominant Hodgkin lymphoma treated in German Hodgkin Study Group trials had good long-term outcomes overall.

Omitting Radiation From Treatment for Early-Stage Hodgkin Lymphoma Increases Risk of Recurrence

Two presentations at the American Society for Radiation Oncology (ASTRO) Annual Meeting offered more evidence that omitting radiation therapy leads to higher rates of recurrence for patients with early-stage Hodgkin lymphoma.

Advertisement


Advertisement